Strategies for optimizing pain management after ureteroscopy
Tracy Cheung,Dima Raskolnikov,Alex Small,Kara L. Watts
DOI: https://doi.org/10.21037/tau-24-45
2024-07-19
Translational Andrology and Urology
Abstract:Tracy Cheung 1 , Dima Raskolnikov 1,2 , Alex Small 1,2 , Kara L. Watts 1,2 1 Albert Einstein College of Medicine, Bronx, NY, USA; 2 Department of Urology, Montefiore Medical Center, Bronx, NY, USA Comment on: Rosen GH, Hargis PA, Kahveci A, et al . Randomized Controlled Trial of Single-dose Perioperative Pregabalin in Ureteroscopy. J Urol 2023;210:517-28. Keywords: Ureteroscopy (URS); pain; stent Submitted Jan 19, 2024. Accepted for publication Jun 16, 2024. Published online Jul 15, 2024. doi: 10.21037/tau-24-45 The prevalence of kidney stones in the United States has nearly doubled since the 1990s, affecting roughly one in 11 individuals (1). This surge in stone disease may be compounded by the effects of climate change, as elevated temperatures increase risk for kidney stones (2). Ureteroscopy (URS) is a common and effective procedure for stone removal; however postoperative pain, stent-related symptoms, and unplanned healthcare encounters can significantly affect patients' quality of life (3). Thus, considerable research has been dedicated to identifying optimal medications or regimens to mitigate patient pain and discomfort through peri-, intra-, and post-operative approaches. Several new, high-quality studies have expanded the knowledge base on this topic, looking at nonsteroidal anti-inflammatory drugs (NSAIDs), pregabalin, local anesthetics, drug combinations and alternative remedies. NSAIDs have been shown to be highly effective for reducing pain after URS. The 2021 SKOPE trial, a randomized, double-blinded, placebo-controlled study, investigated the effectiveness of NSAIDs compared to opioids for post-URS pain control (4). This study compared ketorolac to oxycodone and showed that NSAIDs provided pain control that was non-inferior to opioids and, notably, led to a shorter recovery period. The outcomes of the SKOPE trial were corroborated by Demasi et al. in 2022, who conducted a randomized controlled trial comparing ketorolac to oxycodone-acetaminophen for pain control post-URS (5). Similarly, ketorolac was found to be non-inferior to opioids, furthering support for opioid-sparing medication protocols. In 2022, Bevill et al. also studied NSAIDs in a broader cohort including older patients, those on anticoagulation, and those experiencing chronic pain (3). In these patients, selective cyclooxygenase-2 (COX-2) inhibitor yielded comparable pain control without the potential risks associated with non-specific COX inhibitors which carry a risk of gastric and renal toxicity in longer courses. Combinations of drugs have also been utilized to reduce symptoms after URS. In a 2023 meta-analysis assessing optimal post-URS pain control regimens, Hinojosa-Gonzalez et al. determined that the combination of an alpha-1 blocker, silodosin, and an anticholinergic, solifenacin, to the be the most effective at for pain control post-URS. This was followed by silodosin alone, solifenacin alone, and the combination of solifenacin and pregabalin. This study included assessment of urinary symptoms, pain and sexual performance (6). In a contrasting study published in 2023, Rosen et al. conducted a prospective, single-center, double-blinded, randomized controlled trial of the effect of a single, preoperative dose of pregabalin versus placebo on pain after URS (7). The primary outcome was patient-reported pain levels one hour after URS. Secondary outcomes included additional pain scores at various intervals, medication prescriptions in the month after surgery, post-operative communications with the urology team, emergency department visits, and re-admissions. Patients who received pregabalin actually showed increasedpain scores compared to the placebo group. There were no measurable differences in recovery room time, patients receiving discharge opioids, or quantity discharge opioids between groups. Collectively, these findings demonstrated that pregabalin did not offer a clinically significant benefit pain reduction. Even after controlling for age and preoperative pain scores through multivariable analysis, the results consistently indicated increased pain scores in patients who received pregabalin. This study stands out as a novel addition to the research on medication regimens for discharge planning, offering a distinctive perspective and contributing to the expansion of the limited literature on this subject. Some alternative remedies have also been examined. A 2023 study showed that cannabinoid (CBD) oil lacked a significant impact on pain scores when compared to placebo (8). This finding was possibly limited by the utilization of the lowest dose of CBD in the study. In contrast to the considerable research evaluating regimens for post-operative pain control, studies evaluating intra- and pre-operative medications remain relati -Abstract Truncated-
urology & nephrology,andrology